Asthma and COPD Drugs Market (By Diseases: Asthma, COPD; By Medication Class: Combination Drugs, Bronchodilators, Inhaled Corticosteroids (ICS), Short Acting Beta Agonists (SABA), Long Acting Beta Agonists (LABA), Leukotriene Antagonists (LTA), Anticholinergics, Anti-Inflammatories, Others; By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032

The global asthma and COPD drugs market size was exhibited at USD 37.96 billion in 2022 and is projected to hit around USD 40.05 billion by 2032, growing at a CAGR of 5.5% during the forecast period 2023 to 2032.

asthma and COPD drugs market size

Key Pointers:

  • The CPOD segment is fastest growing segment of the asthma and COPD drugs market in 2022
  • The inhaled corticosteroids (ICS) segment is fastest growing segment of the asthma and COPD drugs market in 2022
  •  The main factor for the growth of asthma and COPD drugs market in North America region is rising prevalence of asthma and COPD
  • Europe, on the other hand, is expected to develop at the fastest rate during the forecast period.

Asthma and COPD Drugs Market Report Scope

Report Coverage Details
Market Size in 2023 USD 40.05 Billion
Market Size by 2032 USD 64.84 Billion
Growth Rate from 2023 to 2032 CAGR of 5.5%
Base year 2022
Forecast period 2023 to 2032
Segments covered Diseases, Medication Class, Distribution Channel
Regional scope North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa
Key companies profiled Pfizer Inc., Teva Pharmaceutical Industries Ltd, Merck & Co. Inc, Grifols S.A., Novartis AG, Cipla Inc., Abbott, Astellas Pharma, Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals

Asthma is a non-communicable, chronic inflammatory lung disorder of the airways. Airways hyper-responsiveness leads to recurrent episodes of wheezing, breathlessness, chest tightness, and cough. Asthma is largely reversible as compared to other obstructive lung diseases. Allergy is the strongest risk factor for asthma. Moreover, asthma can be triggered by exposure of irritants, exercise, β blockers, cold air, animals, and dust. The chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not fully reversible. COPD includes emphysema; a complex lung disease characterized by damage to alveoli and chronic bronchitis; a chronic inflammation to lower respiratory track. Tobacco smoking is the major cause for COPD. In addition, passive smoking, occupational exposure, and ambient air pollution are risk factors for COPD.

The asthma and COPD can be diagnosed with physical examination and several tests such as X-ray, sputum eosinophils, and nitric oxide test. Asthma and COPD can be treated with inhaled corticosteroids, leukotriene modifiers, and theophylline. However, acute respiratory attack can be controlled with the short-acting beta agonists and anticholinergic drugs.

The growth of the global Asthma and COPD Drugs Market is majorly driven by the increase in prevalence of asthma and COPD. For instance, according to world health organisation (WHO), asthma affected an estimated 262 million people and caused 46,1000 deaths in 2019. Furthermore, the rise in number of COPD patients contributes to the growth of market. For instance, according to American Lung Organization, 99 million adults had chronic bronchitis and 2 million adults had emphysema in U.S. in 2018. 

Moreover, advancement in respiratory diseases therapy and new product launches in the global Asthma and Chronic Obstructive Pulmonary Disease Drugs Market are anticipated to contribute toward the growth of the market. For instance, in December 2020, AstraZenca, a leading manufacturer of pharmaceuticals, received EU Approval for ‘Trixeo Aerosphere’ for maintenance treatment of COPD. However, high cost of associated asthma treatment restricts the market growth during the forecast period.

Some of the prominent players in the Asthma and COPD Drugs Market include:

  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd
  • Merck & Co. Inc
  • Grifols S.A.
  • Novartis AG
  • Cipla Inc.
  • Abbott
  • Astellas Pharma
  • Hoffmann-La Roche Ltd
  • Glenmark Pharmaceuticals

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Asthma and COPD Drugs market.

By Diseases

  • Asthma
  • COPD

By Medication Class

  • Combination Drugs
  • Bronchodilators
  • Inhaled Corticosteroids (ICS)
  • Short Acting Beta Agonists (SABA)
  • Long Acting Beta Agonists (LABA)
  • Leukotriene Antagonists (LTA)
  • Anticholinergics
  • Anti-Inflammatories
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Report Detail

  • Report Code:7886
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 4500
USD 7900

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers